2012 · 10 citations · 175 references
Health ProfessionsOphthalmologyPharmacoeconomicsHealth InsuranceOcular DiseaseOphthalmic EpidemiologyComprehensive Eye ExaminationGlaucomaGlaucoma EpidemiologyAngle-closure Glaucoma EpidemiologyAngle-closure Glaucoma ManagementGlaucoma Medications In ChildrenIntraocular Pressure ManagementOpen-angle Glaucoma EpidemiologyOpen-angle Glaucoma Management
The aim of this 11-year retrospective study was to evaluate the impact of two spending patterns in glaucoma care on patient outcomes. Two cities were selected to the study because the statistics of Finnish Social Insurance Institution have repeatedly shown a difference in their mean costs of glaucoma medications per patient, i.e. Oulu spending more and Turku less than the national average. Patients with newly diagnosed open angle in 1994–96 were identified from the national register for reimbursement of medication costs. Patients were 45–74 years old when treatment was initiated after which they had consistently used glaucoma medication ≥ 10 years. For availability of cost data, their place of residence was required to remain unchanged during 1994–2006. In 2006 Social Insurance Institution sent invitations to 360 patients of whom 168 patients (47%) participated and completed the protocol (85 in Oulu and 83 patients in Turku). All patients underwent an ophthalmic examination (visual acuity, intraocular pressure, visual field test, retinal nerve fiber layer and optic disc photography). In addition, patients filled out the 15D health related quality of life questionnaire. All costs of glaucoma care during 11 years were collected for each patient individually. For each follow up year, the total cost was added up including medications, physician visits, diagnostic and follow-up tests as well as laser or surgical procedures. The total 11-year costs of glaucoma care per patient were 35% higher in Oulu (6010 €) compared to Turku (4452 €). Total costs increased with worsening of the disease. After 11 years on treatment, 40% of patients did not show any structural or functional damage. Medication costs accounted up to 73% of total costs. In addition to 29% higher medication costs in Oulu, other than medication costs were also 46% higher in Oulu. In different stages of glaucoma, more treatments (medication, laser and surgery) and more tests (photographs and visual fields) were taken in Oulu. In spite of the higher resource consumption, the 15D instrument did not indicate better quality of life in patients living in Oulu. There was actually a statistically significant counterintuitive difference in the early glaucoma group, i.e. patients using more resources reported worse quality of life. This is the first study evaluating the impact of high resource utilization on quality of life and reporting 15D utility values in different stages of glaucoma. Results from this study indicate that the higher resource allocation may not always lead to measurable benefits to the patients or society in terms of less glaucoma-induced visual disability and/or better quality of life. Further data from randomized trials with both unselected populations as well pragmatic randomized trials of ‘usual patients’ with large sample sizes are required.
175
Global data on visual impairment in the year 2002.
Serge Resnikoff, Donatella Pascolini, Daniel Etya’ale et al. · PubMed · 2004 · 4.2K citations
The Ocular Hypertension Treatment Study
Michael A. Kass · Archives of Ophthalmology · 2002 · 3.7K citations · Full text
The Ocular Hypertension Treatment Study
Mae O. Gordon · Archives of Ophthalmology · 2002 · 2.6K citations